If you have been reading about lyophilized powder and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 3.4 to 3.6 kDa | Depends on whether the affinity complex is attached |
| Appearance | White to off-white lyophilized powder | Freeze-dried solid, often in a sealed vial |
| Solubility | Soluble in water and aqueous buffers | Dissolution rate varies with pH and buffer salt |
| Typical storage | Below minus 20 degrees Celsius, dry and dark | Dissolved material is usually kept cold and used promptly |
| Common analytical methods | Reversed-phase HPLC and mass spectrometry | Peptide mapping and amino acid analysis add sequence detail |
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Lyophilized material is generally stable for extended periods when held at minus twenty degrees Celsius or below and protected from moisture and light. In solution the peptide is more labile; bond hydrolysis, aggregation and oxidation of susceptible residues all proceed faster at ambient temperature. Repeated freeze and thaw cycles should be avoided because they promote clumping and loss of soluble material. The conjugated variant adds a further consideration, since the maleimide group can hydrolyze in aqueous buffer and lose its ability to react with albumin.
Laboratory handling centers on minimizing exposure to water, heat and oxygen before use. Working solutions are typically prepared in sterile water or a mild buffer, and any residual particulate matter is removed by filtration. When the powder dissolves slowly, a small proportion of acetonitrile or dilute acetic acid is sometimes added as a co-solvent. Containers are kept sealed and desiccated between uses. Records of lot number, reconstitution date and storage conditions support later comparison of results across experiments.
Identity and purity are established with reversed phase high performance liquid chromatography coupled to mass spectrometry. The chromatographic step separates the target peptide from truncated sequences and deletion products, while the mass measurement confirms the expected molecular weight to within a fraction of a dalton. Because the two common variants differ by the presence of the linker, mass alone can distinguish them in the unconjugated state. Amino acid analysis and peptide mapping are used when sequence level confirmation is required.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Hitler seemed like the 'double' of a real person, as if Hitler the man might be hiding inside like an appendix, and deliberately so concealed in order not to disturb the mechanism ... You know you could never talk to this man; because there is nobody there ... It is not an individual; it is an entire nation. In an interview in 1949, Carl Jung said,
== Further reading == Shearer, Benjamin; Shearer, Barbara (1997). Notable women in the physical sciences : a biographical dictionary (1. publ. ed.). Westport, Conn. [u.a.]: Greenwood Press. ISBN 9780313293030. Busch-Vishniac, Ilene; Busch, Lauren; Tietjen, Jill (2024). "Chapter 12. Mary Engle Pennington". Women in the National Inventors Hall of Fame: The First 50 Years. Springer Nature. ISBN 9783031755255.
=== Religious use === Use of DET by Alan Birnbaum played an important role in the development and beliefs of his psychedelic church The Temple of the True Inner Light, which subsequently employed the unscheduled and hence dipropyltryptamine (DPT) as well as other psychedelics as sacraments.
==== Urea cycle ==== In the urea cycle, ornithine is converted to citrulline, then to arginine, and finally (through cleavage of urea) back to ornithine. The cycle is necessary because direct conversion of ammonia into urea is not possible under physiological conditions. Carbamoyl phosphate is formed from ammonia and carbon dioxide and enters the cycle. The carbon and one nitrogen atom are incorporated into urea, while the second nitrogen atom is derived from aspartate. Urea is produced in the liver and transported via the bloodstream to the kidney, where it is excreted in the urine. In urine, urea accounts for approximately 90% of the nitrogen content. In the mitochondrion, ornithine is converted with carbamoyl phosphate to citrulline by ornithine transcarbamoylase. The subsequent reactions occur in the cytosol. Citrulline and aspartic acid are converted by argininosuccinate synthase to argininosuccinate. This compound is then converted to arginine by argininosuccinate lyase, releasing fumarate. Arginine can subsequently be converted back to ornithine by arginase with the release of urea, thereby completing the cycle. Nitrogen excretion in the form of urea occurs in mammals, whereas fish typically excrete ammonium directly, and reptiles and birds excrete uric acid.
Sources: en.wikipedia.org
Skittles, a brand name of candy products produced by the Wm. Wrigley Jr. Company, come in a wide variety of flavors. Most of the varieties are available only in particular regions of the world. The first flavor was Original Fruit Skittles, first released in Europe in 1974, and then in the United States in 1979. Earlier Skittles products tended to focus on fruit flavors; more recent products have branched out to include flavors such as chocolate, bubble gum, popcorn, mint, and sours. The original Skittles flavors in the United States (and other countries except for Europe) are orange, lemon, lime, grape and strawberry. In 2013, Skittles changed its original flavor line-up to include green apple, causing a consumer backlash. Green apple also replaced lime in the sour packets. It was rumored that the reason behind this is the green apple flavor outperforming lime in taste tests. A "Long Lost Lime" variation of Skittles was released in summer 2017 and 2018, bringing the lime flavor back to the original mix of Skittles for a limited time only. In September 2021, it was announced that lime would be permanently returning to the original Skittles flavor in October 2021, replacing green apple for the first time since 2013.
=== Ornithine decarboxylase === Ornithine decarboxylase (ODC), is a labile protein that is the first rate-limiting enzyme in polyamine biosynthesis. Its degradation is regulated by antizyme that is induced by polyamine production. NQO1 has been shown to stabilize the degradation of ODC by binding to it and protecting it from 20S proteasomal degradation.
=== CaMK2A === CaMKIIA is one of the major forms of CamKII. It has been found to play a critical role in sustaining activation of CamKII at the postsynaptic density. Studies have found that knockout mice without CaMKIIA demonstrate a low frequency of LTP. Additionally, these mice do not form persistent, stable place cells in the hippocampus.
Sources: en.wikipedia.org
Architectural propaganda is the use of architecture for the purpose of propaganda. Throughout history, significant architectural works have been used to convey ideas, including many intended to command respect and obedience.
== Further reading == Genck, Wayne (7 November 2010). "Make The Most of Antisolvent Crystallization". Chemical Processing. Putman Media. Retrieved 12 June 2025. Sheehan, David (2009). Physical Biochemistry: Principles and Applications. John Wiley & Sons. p. 285. ISBN 978-0-470-85602-4. Miller, S A; Dykes, D D; Polesky, H F (11 February 1988). "A simple salting out procedure for extracting DNA from human nucleated cells". Nucleic Acids Research. 16 (3): 1215. CiteSeerX 10.1.1.941.1917. doi:10.1093/nar/16.3.1215. PMC 334765. PMID 3344216. {{cite journal}}: Cite uses deprecated parameter |citeseerx= (help) McKay, H. A. C. (1 January 1953). "Activities and activity coefficients in ternary systems". Transactions of the Faraday Society. 49: 237–242. doi:10.1039/TF9534900237.
Pa s. This is about a ten thousand times that of water at room temperature, but it is small enough to enable the LAF-1 droplets to flow like a liquid. Generally, interaction strength (affinity) and valence (number of binding sites) of the phase separating biomolecules influence their condensates viscosity, as well as their overall tendency to phase separate.
The program features engineers and architects from around the world, including Santiago Calatrava; italian structural engineer Mario Salvadori of Columbia University; Danish civil engineer and bridge designer Klaus Ostenfeld, and grandson of civil engineer Asger Ostenfeld; civil engineer Mark Whitby and the innovative Severn Bridge, which deployed box girders; Irish civil engineer Patrick J. Dowling, head of the Department of Civil and Environmental Engineering, Imperial College London; the Severn Bridge was taking much heavy traffic at 4-6 am each weekday morning, the amounts of heavy traffic that it had not been inherently designed for, in the late 1950s to take, and the bridge was strengthened in 1990; David Blockley, head of civil engineering at the University of Bristol, and earthquake protection; the 1989 Loma Prieta earthquake; Colin Taylor, head of civil engineering from 2006-11 at the University of Bristol; the Jinde Bridge; the Japanese Great Seto Bridge opened in April 1988; the Pont de Normandie was twice as large of any previous similar type of bridge, and its 206m towers were completed in July 1993, being 250m longer than the 1993 Yangpu Bridge; French civil engineer Michel Virlogeux, and the project manager Bertrand Deroubaix; tuned mass dampers; Spanish structural engineer Santiago Calatrava, who designed the 1992 Alamillo Bridge and 1991 Lusitania Bridge in Mérida, Spain; Peter Head (civil engineer) of Maunsell Group (now AECOM).
Sources: en.wikipedia.org
The version carrying the affinity complex bears a maleimide group that binds serum albumin, which extends its circulation time to several days. The version without it lacks this group and clears within roughly half an hour. The two are chemically related but behave very differently once in the body.
In common usage the name without the affinity complex is often equated with MOD GRF 1-29, a fragment carrying four stabilizing substitutions. Strictly speaking, the term originally referred to the albumin-binding version. The overlap in naming causes frequent ambiguity in both informal and technical writing.
Reversed-phase chromatography separates the peptide from related impurities and yields a purity estimate. Mass spectrometry confirms the molecular mass and detects modifications such as oxidation. Sequence-level checks rely on peptide mapping or amino acid analysis when stronger confirmation is needed.
No. It is a laboratory-made analog of growth hormone-releasing hormone. The natural hormone is a 44-residue peptide, while the analog is built on a shorter 29-residue fragment.